The stock rallied 14.3% post-earnings, driven by broad-based strength in the Commercial segment, particularly robust subscription growth, and strong initial momentum in AI initiatives including the new Veeva Falcon offering.
Veeva delivered robust financial results for Q4 and the full fiscal year 2026, exceeding revenue expectations and achieving a notable $3.195 billion in annual revenue, underscoring its position as a key player in the life sciences sector.